Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

New Horizon Health: Positive Alert, Upgrades '23 Revenue Guidance

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

<ul>
<li>New Horizon reported a strong 1H2023 results. Company has upgraded its '23 sales guidance.</li>
<li>The company will continue to deliver strong sales growth despite recent anti-corruption movement in China.</li>
<li>We believe that the evidence presented by the recent short-selling report is not sound. We believe the impact is over. </li>
</ul>


New Horizon reported a strong 1H2023 results. Company has upgraded its '23 sales guidance.
The company will continue to deliver strong sales growth despite recent anti-corruption movement in China.
We believe that the evidence presented by the recent short-selling report is not sound. We believe the impact is over. 


2024 High Conviction - New Horizon Health - Overhangs Are Over, Upgraded '23 Guidance